Work

PP01.55: RASolve 301: A Phase 3 Study of Daraxonrasib (RMC-6236) vs. Docetaxel in Patients with Previously Treated RAS-Mutant NSCLC

Year: 2026

Type: conference-abstract

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2026.103798

Authors: Ferdinandos Skoulidis, Kathryn C. Arbour, Sanjay Popat, Colin R. Lindsay, Hidehito Hironouchi, Gérard Zalcman, Alessandra Curioni-Fontecedro, Jarushka Naidoo, Adrianus J. de Langen, Jing He, Erica Su, Minoti Hiremath, Lawrence Watt, Achim Rittmeyer, Melissa Johnson

Institutions: The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Royal Marsden Hospital, The Christie Hospital, National Cancer Center Hospital, Hôpital Bichat-Claude-Bernard, HFR Freiburg Kantonsspital, Beaumont Hospital, The Netherlands Cancer Institute, Revolution Medicines (United States), Sarah Cannon

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7160488690

Cites:

Cited by:

Related to: